We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

TeraRecon to Sell EnvoyAI Platform

By HospiMedica International staff writers
Posted on 12 Dec 2017
Image: TeraRecon has entered into a distribution partnership with EnvoyAI to sell and market the EnvoyAI platform (Photo courtesy of TeraRecon).
Image: TeraRecon has entered into a distribution partnership with EnvoyAI to sell and market the EnvoyAI platform (Photo courtesy of TeraRecon).
TeraRecon (Foster City, CA, USA), a provider of advanced visualization solutions, has entered into a distribution partnership with EnvoyAI (Cambridge, MA, USA) to sell and market the EnvoyAI platform. The platform includes a content-rich artificial intelligence (AI) marketplace, called the EnvoyAI Exchange, as well as a suite of market-ready AI-enablement technologies aimed at fostering broader access and clinical use of medical imaging algorithms within busy radiology practices.

TeraRecon provides advanced visualization, image viewing and post-processing solutions that leverage AI to improving radiology workflow through personalized automation features for increased efficiency. EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end-users. It facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.

As a distributor of EnvoyAI, TeraRecon will offer instant access to the platform containing more than 35 algorithms and initially focus on driving sales on two FDA-cleared algorithms from Imbio and icometrix, as well as one of its own cleared algorithms. Imbio offers lung density reporting for COPD analysis with chest CT scans. The Imbio CT Lung Density Analysis software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support for diagnosis and follow up examinations. icometrix offers icobrain, an FDA-cleared brain MRI tool that is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. The software is intended to automate the current manual process of identifying, labeling and quantifying the volumes of segmentable brain structures identified on MR images. TeraRecon offers iNtuition Time Density Analysis for CT, which supports stroke triage workflow by producing colorized parametric maps of the brain from time-resolved, thin-slice CT scans of the head with contrast, including CBF, CBV, MTT, TTP, TOT, RT map types.

“The automated outputs from Imbio and icometrix elevate the standard of care without creating additional work for radiologists,” said Jeff Sorenson, President and CEO of TeraRecon. “The combined workflows achieved by TeraRecon and EnvoyAI deliver these results in a fast, flexible, and extensible way allowing our customers to easily introduce AI into their medical imaging enterprise.”

Gold Member
CPAP Ventilator
Somnus DM18
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Pressure Guidewire
SavvyWire
New
Mobile X-Ray System
K4W

Channels

Surgical Techniques

view channel
Image: The novel approach combining MRI, fluid dynamics, and custom algorithms predicts brain cancer recurrence sites (photo courtesy of AdobeStock)

Novel Method Uses Interstitial Fluid Flow to Predict Where Brain Tumor Can Grow Next

Glioblastoma is one of the most aggressive brain cancers, with patients surviving on average only 15 months after diagnosis. Surgery and radiation can temporarily control the tumor, but the disease almost... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more